Leptin targets in the mouse brain
Description CJC-1295 NO DAC + Ipamorelin GHRH Analog & GHRP Research Blend Research Overview This is a research blend combining two distinct peptides that engage the growth hormone (GH) axis through complementary mechanisms: CJC-1295 (no DAC), a modified GHRH (growth hormone-releasing hormone) analog, and Ipamorelin, a selective ghrelin receptor (GHSR-1a) agonist functioning as a growth hormone-releasing peptide (GHRP)
GLP-1 therapeutic effects
L-carnitine and acetyl-L-carnitine enhance mitochondrial activity and energy metabolism by restoring the NAD(H)/NADP(H) ratio, thereby mitigating ROS-induced damage
Improved adherence Side effects have been called out as a main reason that people stop taking a GLP-1
The $279/$179 first-month rates arent a teaser, they roll to $349 tirzepatide and $249 semaglutide flat across every dose, with no membership, no dose-tier escalation, and no concierge fee stacked at checkout